Quetiapine Vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder - Full Text View

Quetiapine Vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

This study has been completed.

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00018642

Purpose

The purpose of this research study is to determine whether a new drug for schizophrenia is better for the maintenance treatment than a standard drugs currently prescribed. The new medication is called quetiapine and it will be compared with a standard medication called haloperidol decanoate. The study will determine if quetiapine causes fewer problems than haloperidol with side effects such as stiffness and restlessness and whether it costs the VA more or less to treat patients with quetiapine. In addition, blood samples will be collected every three months to determine if certain chemicals in the blood can influence the outcome of the subjects' illness.

Condition	Intervention
Schizophrenia Schizoaffective Disorder	Drug: quetiapine Drug: haloperidol decanoate

MedlinePlus related topics:

Schizophrenia

Drug Information available for:

Quetiapine Quetiapine fumarate Haloperidol Haloperidol decanoate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Uncontrolled, Parallel Assignment, Efficacy Study

Official Title:	Predicting the Optimal Pharmacotherapy for Outpatients With Schizophrenia

Further study details as provided by Department of Veterans Affairs:

Study Start Date:	April 1997
Estimated Study Completion Date:	March 2002

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Schizophrenia or Schizoaffective Disorder diagnosed by DSM-IV
Between the ages 18-60.
A candidate for maintenance antipsychotic therapy. This means that patients will have had at least two documented episodes of acute schizophrenic illness or at least two years of continuing psychotic symptoms.

Exclusion Criteria

Organic brain disease.
Mental Retardation
Chronic medical illness which would make antipsychotic medication inappropriate.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018642

Locations


United States, California
	VA Greater Los Angeles Healthcare System
	Los Angeles, California, United States, 90073

Sponsors and Collaborators

Department of Veterans Affairs

More Information

Study ID Numbers:	MHBS-042-96F
First Received:	July 3, 2001
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00018642
Health Authority:	United States: Federal Government

Keywords provided by Department of Veterans Affairs:

quetiapine

haloperidol decanoate

Study placed in the following topic categories:

Haloperidol

Schizophrenia

Haloperidol decanoate

Quetiapine

Dopamine

Mental Disorders

Psychotic Disorders

Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Neurotransmitter Agents

Disease

Tranquilizing Agents

Molecular Mechanisms of Pharmacological Action

Anti-Dyskinesia Agents

Physiological Effects of Drugs

Gastrointestinal Agents

Psychotropic Drugs

Central Nervous System Depressants

Antiemetics

Dopamine Antagonists

Antipsychotic Agents

Pharmacologic Actions

Pathologic Processes

Autonomic Agents

Therapeutic Uses

Dopamine Agents

Peripheral Nervous System Agents

Central Nervous System Agents

ClinicalTrials.gov processed this record on November 20, 2008